Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

500 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies.
Hunter SF, Aburashed RA, Alroughani R, Chan A, Dive D, Eichau S, Kantor D, Kim HJ, Lycke J, Macdonell RAL, Pozzilli C, Scott T, Sharrack B, Wiendl H, Chung L, Daizadeh N, Baker DP, Vermersch P; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. Hunter SF, et al. Among authors: vermersch p. Neurol Ther. 2021 Dec;10(2):803-818. doi: 10.1007/s40120-021-00262-3. Epub 2021 Jun 24. Neurol Ther. 2021. PMID: 34165694 Free PMC article.
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
Gold R, Piani-Meier D, Kappos L, Bar-Or A, Vermersch P, Giovannoni G, Fox RJ, Arnold DL, Benedict RHB, Penner IK, Rouyrre N, Kilaru A, Karlsson G, Ritter S, Dahlke F, Hach T, Cree BAC. Gold R, et al. Among authors: vermersch p. J Neurol. 2022 Sep;269(9):5093-5104. doi: 10.1007/s00415-022-11166-z. Epub 2022 May 31. J Neurol. 2022. PMID: 35639197 Free PMC article. Clinical Trial.
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.
de Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Wiendl H, Keller B, Roy S; MAGNIFY-MS Study Group. de Stefano N, et al. Among authors: vermersch p. Neurol Neuroimmunol Neuroinflamm. 2022 Jun 14;9(4):e1187. doi: 10.1212/NXI.0000000000001187. Print 2022 Jul. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35701185 Free PMC article.
Diagnosis and treatment of progressive multiple sclerosis: A position paper.
Pozzilli C, Pugliatti M, Vermersch P, Grigoriadis N, Alkhawajah M, Airas L, Oreja-Guevara C. Pozzilli C, et al. Among authors: vermersch p. Eur J Neurol. 2023 Jan;30(1):9-21. doi: 10.1111/ene.15593. Epub 2022 Oct 25. Eur J Neurol. 2023. PMID: 36209464 Free PMC article. Review.
Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review.
Fernández Ó, Sörensen PS, Comi G, Vermersch P, Hartung HP, Leocani L, Berger T, Van Wijmeersch B, Oreja-Guevara C. Fernández Ó, et al. Among authors: vermersch p. Front Immunol. 2024 Apr 5;15:1379538. doi: 10.3389/fimmu.2024.1379538. eCollection 2024. Front Immunol. 2024. PMID: 38646534 Free PMC article. Review.
500 results